Effectiveness of Baclofen in the Treatment of People With Bulimia Nervosa or Binge Eating Disorder
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will evaluate the effectiveness of the drug baclofen in reducing binge eating and associated food cravings in people with bulimia nervosa or binge eating disorder.
| Condition | Intervention |
|---|---|
|
Eating Disorders Bulimia Nervosa |
Drug: Baclofen |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effects of Baclofen on Binge Eating in Bulimia Nervosa and Binge Eating Disorder |
- Frequency of binge eating [ Time Frame: Measured at Week 13 ] [ Designated as safety issue: No ]
- Cravings associated with binge eating [ Time Frame: Measured at Week 13 ] [ Designated as safety issue: No ]
| Enrollment: | 10 |
| Study Start Date: | April 2005 |
| Study Completion Date: | June 2007 |
| Primary Completion Date: | June 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Participants will take baclofen for 10 weeks.
|
Drug: Baclofen
Participants will take baclofen 3 times a day, before meals, for 10 weeks. Baclofen dosages will be low to begin, followed by a gradual increase over a 2-week period. Upon reaching the maximum tolerated dose of baclofen, participants will continue at this dosage level until Week 11, at which time the dose will be gradually decreased. If any serious side effects occur, baclofen dosage will be decreased to the previous tolerated dosage level.
|
Detailed Description:
Bulimia nervosa (BN) and binge eating disorder (BED) are serious eating disorders that are characterized by frequent uncontrolled eating binges. Binge eating is associated with both psychological and physical health problems, such as depression, obesity, stomach problems, and heart problems. Treatment options for binge eating, however, are limited. Baclofen, a drug that enhances the GABA-B neurotransmitter's ability to inhibit neuronal activity in the brain, is commonly used as a muscle relaxant. It has also been shown, however, to have positive effects on binge eating when used in animals and on substance abuse when used in humans. This study will evaluate the effectiveness of baclofen in reducing binge eating and associated food cravings in people with BN or BED.
People interested in participating in this study will first report to the study site for two initial visits, which will involve blood tests and interviews regarding medical history. If eligible, participants will take part in this 13-week open-label study. Participants will take baclofen 3 times a day, before meals, for 10 weeks. Baclofen dosages will be low to begin, followed by a gradual increase over a 2-week period. Upon reaching the maximum tolerated dose of baclofen, participants will continue at this dosage level until Week 11, at which time the dose will be gradually decreased. If any serious side effects occur, baclofen dosage will be decreased to the previous tolerated dosage level. Participants will also keep a daily record of any episodes of binge eating. Study visits will be held biweekly. At each visit, participants will be interviewed by a psychiatrist about their mental health history and eating patterns, and will fill out questionnaires about their eating habits, emotional states, and any side effects. Phone interviews will be conducted during the weeks in between study visits.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
For people with BN:
- Meets DSM-IV criteria for BN
- Disease duration is more than 1 year
- Self-induces vomiting
- Weighs between 80 and 120% of ideal weight
- Binge eats on at least 6 days during the 2-week run-in period
For obese people with BED:
- Meets DSM-IV criteria for BED
- Obese (body mass index [BMI] is greater than 30 kg/m²)
- Binge eats on at least 6 days during the 2-week run-in period
Exclusion Criteria:
For all participants:
- Significant medical illness
- Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder as defined by DSM-IV-TR
- Moderate to severe depression as defined by a score greater than 18 on the Hamilton Depression Scales
- Current DSM-IV-TR diagnosis of organic mental disorder, factitious disorder, or malingering
- History of a personality disorder (e.g., schizotypal, borderline, or antisocial) that might interfere with assessment or compliance with the study procedures
- At risk for suicide
- Currently taking medication other than birth control pills or over-the-counter medication
- History of drug or alcohol abuse within 3 months prior to study entry
- Pregnant, planning to become pregnant, or breast feeding
- Known intolerance to baclofen, or related muscle relaxants
- Orthostatic hypotension
Additional exclusion criteria for people with BN:
- Underweight (BMI less than 18 kg/m²)
Contacts and Locations| United States, New York | |
| Eating Disorders Clinic, New York State Psychiatric Institute | |
| New York, New York, United States, 10032 | |
| Principal Investigator: | B. T. Walsh, MD | New York State Psychiatric Institute at Columbia University Medical Center |
More Information
No publications provided
| Responsible Party: | Dr. B. Timothy Walsh, The New York State Psychiatric Institute |
| ClinicalTrials.gov Identifier: | NCT00320047 History of Changes |
| Other Study ID Numbers: | R21 MH65024-06, DNBBS 72-NBR |
| Study First Received: | April 28, 2006 |
| Last Updated: | September 18, 2009 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institute of Mental Health (NIMH):
|
Binge Eating Disorder |
Additional relevant MeSH terms:
|
Bulimia Binge-Eating Disorder Eating Disorders Bulimia Nervosa Hyperphagia Signs and Symptoms, Digestive Signs and Symptoms Mental Disorders Baclofen GABA-B Receptor Agonists GABA Agonists |
GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Muscle Relaxants, Central Neuromuscular Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 18, 2013